As RadioVal approaches its second anniversary in just a few months, we take a moment to reflect on a journey that has been marked by innovation and dedication, and we are eager to share the exciting developments and objectives we are currently pursuing.
Year Two Outlook
International Study
We announced the commencement of an international study aimed at a comprehensive evaluation of our radiomics tools for breast cancer treatment planning. This study, meticulously planned by our working group, assesses the robustness, fairness, usability, explainability, traceability, and scalability of our radiomics models. By comparing results from both internal and external sites across different countries, we aim to gain a deep understanding of our tools’ performance on a global scale.
Consensus on RadioVal Tool Requirements
Achieving consensus on multidisciplinary requirements remains a key focus. This involves covering clinical, patient, healthcare, socio-ethical, legal, and regulatory aspects. Through stakeholder sessions and Delphi methodologies, we are working towards aligning on these requirements, paving the way for a thorough validation study.
Evaluation Criteria and Metrics
Establishing rigorous evaluation metrics for radiomics-based and AI models in healthcare and medical imaging is ongoing. Our dedicated working group is in the process of finalising these metrics and will soon publish a scientific paper detailing their practical applications. This initiative is crucial for ensuring our models meet the highest standards of reliability and accuracy.
Developing RadioNac
We are advancing the development of RadioNac, which includes models for automated breast tumour segmentation, prediction of breast cancer treatment outcomes, and survival models. By incorporating FUTURE-AI recommendations, we are enhancing the trustworthiness and transparency of our AI models.
Reflecting on Year One
“In our first year of collaboration, we achieved significant milestones and made pivotal decisions for RadioVal. As we look ahead, we are excited about developing cutting-edge AI-powered tools that have the potential to revolutionise breast cancer treatment predictions and strengthen clinical confidence,” said Oliver Diaz, Coordinator of RadioVal.
The first year of RadioVal saw the establishment of a solid foundation, with key achievements in the development and initial testing of our radiomics tools. Our team worked diligently to ensure that our models are scientifically robust and ready for rigorous evaluation.
Moving Forward
With these ongoing initiatives, RadioVal is set to demonstrate further innovation in breast cancer treatment prediction. Our mission is to provide personalised treatment options to patients worldwide, enhancing clinical outcomes and improving the quality of life for those affected by breast cancer.
As we accelerate towards our second anniversary, we are committed to meeting our development goals and objectives. We invite our stakeholders, partners, and the wider medical community to join us in this journey.
Wactch the video below to learn more our project.